The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 3, 2005, Pages 257-263

  Barthel, Henryk ^a,b   Perumal, Meg ^a   Latigo, John ^a   He, Qimin ^c   Brady, Frank ^d   Luthra, Sajinder K ^d   Price, Pat M ^e   Aboagye, Eric O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Hammersmith Imanet   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

18F FLT; ATP; PET; Proliferation; Thymidine kinase 1

Indexed keywords

3' FLUOROTHYMIDINE; ADENOSINE TRIPHOSPHATE; THYMIDINE KINASE 1; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; THYMIDINE KINASE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN VARIANT; RADIOACTIVITY; STATISTICAL SIGNIFICANCE; ANIMAL; ANTIBODY SPECIFICITY; LYMPHOMA; MALE; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; DIDEOXYNUCLEOSIDES; LYMPHOMA; MALE; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; THYMIDINE KINASE; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 17644392076     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1611-0     Document Type: Article

References (35)

1. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001;8(12):1487-503.
2. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004;5:27-36.
3. Workman P. How much gets there and what does it do? the need for better pharmacokinetic and pharmacodynamic end-points in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
4. Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Des 2003;9:917-29.
5. Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Des 2003;9:931-44.
6. 18F]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
7. 3H] arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7.
8. Rasey JS, Grierson JR, Wiens LW, KoLb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-17.
9. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003;44:2027-32.
10. 18F]fluorothymidine as a new marker for monitoring tumor response to anti-proliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-98.
11. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-4.
12. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-23.
13. 18F-FDG. J Nucl Med 2003;44:1426-31.
14. 18F]FLT PET for diagnosis and staging of throacic tumours. Eur J Nucl Med Mol Imaging 2003;30:1407-12.
15. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-6.
16. 18F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res 2004;10:1685-90.
17. Ellims PH, Van der Weyden MB, Medley G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Res 1981;41:691-5.
18. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8.
19. Chang ZF, Huang DY, Hsue NC. Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. J Biol Chem 1994;269:21249-54.
20. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase. I. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89.
21. Olofsson S, Eriksson S, Karlsson A, Oberg B. The HIV replication inhibitor 3′-fluoro-3′-deoxythymidine blocks sialylation of N-linked oligosaccharides. Antiviral Res 1992;19:71-80.
22. 18F]FLT) and the fate of the precursor 2,3′-anhydro-5(-O-(4, 4′-dimethoxytrityl)-thymidine. J Label Comput Radiopharm 2001;44(Suppl 1):871-3.
23. Stephens TC, Smith MN, Waterman SE, McCloskey ML, Jackman A, Boyle FT. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors. Adv Exp Med Biol 1993;338:589-92.
24. Aherne GW, Hardcastle A, Ward E, Dobinson D, Crompton T, Valenti M, et al. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Clin Cancer Res 2001;7:2923-30.
25. Honma M, Hayashi H, Shimada N, Tanaka N, Wakuri S, Awogi T, et al. Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test. Mutagenesis 1999;14:5-22.
26. +/--3.7.2C mouse lymphoma cells. Mutagenesis 2002;17:105-9.
27. Combes RD, Stopper H, Caspary WJ. The use of lymphoma cells to assess the mutagenic, clastogenic and aneugenic properties of chemicals. Mutagenesis 1995;10:403-8.
28. 18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004;90:2232-42.
29. Tommasi S, Pfeifer GP. Constitutive protection of E2F recognition sequences in the human thymidine kinase promoter during cell cycle progression. J Biol Chem 1997;272:30483-90.
30. Liechty MC, Rauchfuss HS, Lugo MH, Hozier JC. Sequence analysis of tka(-)-1 and tkb(+)-1 alleles in L5178Y tk+/-mouse-lymphoma cells and spontaneous tk-/- mutants. Mutat Res 1993;286:299-307.
31. Clive D, Glover P, Krehl R, Poorman-Allen P. Mutagenicity of 2-amino-N6-hydroxyadenine (AHA) at three loci in L5178Y/tk+/- mouse lymphoma cells: molecular and preliminary cytogenetic characterizations of AHA-induced tk-/-mutants. Mutat Res 1991;253:73-82.
32. Oberly TJ, Bewsey BJ, Probst GS. Thymidine kinase activity and trifluorothymidine resistance of spontaneous and mutagen-induced L5178Y cells in RPMI 1640 medium. Mutat Res 1986;161:165-71.
33. Kristensen T, Jensen HK, Munch-Petersen B. Overexpression of human thymidine kinase mRNA without corresponding enzymatic activity in patients with chronic lymphatic leukemia. Leuk Res 1994;18:861-6.
34. Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 1991;11:2538-46.
35. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.